Dr John Haanen presents his open-label phase 3 trial which studied treatment with tumour-infiltrating lymphocytes (TIL) versus ipilimumab for advanced melanoma.  

Adoptive cell therapy with TIL is a treatment modality with promising response rates of 36-70% in patients with advanced melanoma, observed in multiple phase 1/2 trials.

The results demonstrated TIL therapy significantly improved PFS compared to ipilimumab in patients with advanced melanoma, the vast majority being anti-PD-1 refractory, making it a possible new treatment option in this patient population.